Exchange: NASDAQ·Updated 07:34 PM EDT

About

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Braveheart Bio Inc.?
What is the 52-week high for Braveheart Bio Inc.?
What is the 52-week low for Braveheart Bio Inc.?
What is Braveheart Bio Inc. stock price today?
What was Braveheart Bio Inc. stock price yesterday?
What is the Price-to-Book ratio of Braveheart Bio Inc.?
What is the 50-day moving average of Braveheart Bio Inc.?

Advertisement|Remove ads.